Lenalieva (Lenalidomide) Capsule

Generic brands for Lenalidomide Capsule Available in India Brand Name Lenalieva Generic Name Lenalidomide Strength 2.5mg, 5mg, 10mg, 15mg, 20mg, 25mg Manufacturer Allieva Pharma Pvt. Ltd.  

Description

Description

This page contains brief details about the drug lenalidomide, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Lenalidomide is an antiangiogenic agent (a drug that blocks the formation of blood vessels) which was approved for its medical use on 27th December 2005.

Mechanism of Action of Lenalidomide

Lenalidomide is an antiangiogenic agent that works by inhibiting the formation of blood vessels that supplies nutrition to the cancer cells and facilitates the immune system attack against cancer cells. It activates T-cell and Natural Killer cells, suppresses inflammatory mediators like TNFα and other cytokines, arrests the cell cycle and induces programmed cell death of cancer cells. Lenalidomide is used in combination with other treatments like hemopoietic stem cell transplant, dexamethasone, or rituximab.

Uses of Lenalidomide

Lenalidomide has been developed to treat Multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma and follicular lymphoma.

Lenalidomide Dosage available

Lenalidomide is available in the form of capsule in the doses 2.5mg, 5mg, 10mg, 15mg, 20mg, and 25mg. You shall take Lenalidomide capsule with or without food by swallowing the capsule with water once a day. If you have kidney problem, your healthcare provider will adjust the dose after measuring your creatinine clearance.

We can ship to :

News/Updates

References

1. Bristol Myers Squibb, US Food & Drug Administration, [Revised on May 2022] [Accessed on 7th Sep 2022], https://packageinserts.bms.com/pi/pi_revlimid.pdf

2. Anton Wellstein, Giuseppe Giaccone, Michael B. Atkins, and Edward A. Sausville, Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules, Goodman & Gilman’s Pharmacological Basis of Therapeutics, 13th Edition, 2018, 1203-1236.